Metabolic & Atherosclerosis Research Center (MARC)

Cincinnati, Ohio 45227

1 studies enrolling now · 9 studies all time

What they study most

Cardiovascular Disease With Mention of Arteriosclerosis, Cardiovascular Diseases, Cardiovascular Risk Factor, Cardiovascular Stroke, Elevated Cholesterol, Familial Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia, Homozygous Familial Hypercholesterolemia, Hyper-LDL-cholesterolemia, Hypercholesterolemia, LDL Cholesterol

Studies at this site

• Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction — Enrolling by invitation
• Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction — Status unconfirmed
• Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction — Completed
• Study of Efficacy and Safety of LIB003 in Patient With CVD on Statins Requiring Additional LDL-C Reduction — Status unconfirmed
• Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH — Completed
• Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients — Completed
• Cross-Over Study to Compare the Pharmacokinetics and Pharmacodynamics of LIB003 Process 1 and Process 2 Drug Product — Completed
• Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003 — Completed
• Study to Evaluate Efficacy and Safety of LIB003 in Patients on Lipid-Lowering Therapy Needing Additional LDL-C Reduction — Completed